April 14, 2020 – Slone Partners, a nationwide executive search firm for life sciences and diagnostics companies, has announced the placement of Roger D. Klein, M.D., J.D., FCAP, as Chief Medical Officer (CMO) of OmniSeq®. Dr. Klein will support OmniSeq in its continued development of innovative products that help oncologists identify the best precision medicine options for their patients.
“Dr. Klein is a highly accomplished leader in the innovative fields of molecular pathology, oncology and precision medicine,” said Slone Partners President Tara Kochis-Stach. “He will be a tremendously valuable addition to OmniSeq’s executive team.”
Dr. Klein joins OmniSeq with nearly 30-years of experience in the medical industry and a distinguished career in molecular pathology. He previously held leadership roles in molecular pathology at Cleveland Clinic, the BloodCenter of Wisconsin and the H. Lee Moffitt Cancer Center. Dr. Klein received his undergraduate and medical degrees from Case Western Reserve University and completed post-graduate medical education at Yale University School of Medicine and the Mayo Clinic. In addition, he has a law degree from Yale Law School.
“I am thrilled to be joining OmniSeq at an exciting time for cancer diagnostics and precision medicine at a pivotal juncture for the company,” said Dr. Klein. “I look forward to working with OmniSeq’s outstanding and talented team and am dedicated to supporting the organization in its mission to advance precision medicine and improve patient outcomes.”
Founded in 2015, OmniSeq is a commercial, CAP-accredited, CLIA and New York State CLEP-licensed clinical laboratory in Buffalo, New York. The company utilizes next generation sequencing (NGS) technologies through New York State CLEP-approved comprehensive molecular profiling and offers a wide variety of pharmaceutical services to assist in drug development.
Margot Schoenborn, CEO of OmniSeq, remarked, “As our new clinical affairs leader, Dr. Klein will play a critical role in educating oncologists, pathologists and other clinicians on how to leverage molecular information to improve clinical decision-making and therapeutic selection for patients with advanced cancers. He brings insights into treating providers’ needs that will help drive our clinical evidence development initiatives.”
ABOUT SLONE PARTNERS
Slone Partners delivers the leaders who build amazing scientific healthcare organizations – People Are Our Science®. Since 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established life sciences, diagnostics, precision medicine, CRO, and laboratory services companies. With coast-to-coast presence in the most active healthcare industry hubs of Boston, San Francisco, Los Angeles, San Diego, Austin, Research Triangle Park NC, New York, and Washington DC, Slone Partners uniquely and precisely provides an array of executive search and advisory services to innovative scientific healthcare companies. To learn more about Slone Partners’ value proposition and processes, visit www.slonepartners.com or call 888.784.3422.
OmniSeq, an innovation of Roswell Park Cancer Institute, is a molecular diagnostic laboratory based in Buffalo, New York. OmniSeq endeavors to find the right drug or the right trial for every patient by improving access to better cancer treatment options through genomic and immune profiling. OmniSeq offers three NGS-based assays: OmniSeq MSI NGS®, OmniSeq Advance®, and OmniSeq Comprehensive®. For more information about OmniSeq’s clinical products or pharmaceutical services, or to speak with an OmniSeq CARES® specialist, call +1-800-781-1259 or visit www.omniseq.com.